

Identity:

Title: Professor of Cardiology
Family Name(s): Nalbantgil
First Name(s): Sanem
Age: 54 (1969)

Photo:

Application for the following position in the HFA Board or Nominating Committee:
Ordinary Board member

Place of work

If you work in multiple places, please provide the one where you spend the most time or that you consider to be your main place of practice.

| | |
|-------------------------|---|
| Institute/organisation: | Ege University Medical School |
| Department: | Dept of Cardiology |
| Address: | Ege University Medical School Bornova Izmir |
| Post code / Zip: | 35100 |
| Country: | Türkiye |

General Curriculum Vitae (500 words max)

Please also include your H index and top 5 to 10 publications in the last 5 years

I studied medical school at Ege University. I completed my residency on cardiology at the same institution and continued to work in the same hospital. I am a professor of cardiology working at Ege University Medical School, Dept of Cardiology. I have been dealing with advanced heart failure for more than 25 years. My institution is the largest center in the country regarding heart transplantation and mechanical circulatory support. I have participated in the management of more than 300 heart transplant patients and more than 500 long term ventricular assist devices. I also contributed to the rising the awareness of advanced heart failure, heart transplantation and mechanical circulatory support in the country and did succeed to establish a 'heart team' on heart failure as the first in Türkiye.

I am a fellow of ESC and a fellow of HFA. I worked as a member of 'Advanced Heart Failure Committee between 2016 – 2018 and 2018 – 2020 and 2020-2022 and 2022-2024. I participated in the preparation of position papers listed below. I also contributed as a reviewer for ESC Heart Failure and European Heart Journal.

I am a member of ISHLT. I participated in the 'program planning committee' for 2017 and 2018 and 2022 congresses of ISHLT. I am also a member of Turkish Society of Cardiology and working closely with the 'working group of heart failure'. A position paper on advanced heart failure was prepared by this working group and I had the honour of being the editor of the supplement. It was published in 'updates of cardiology', a journal of 'Turkish Society of Cardiology'. This year I and my six distinguished colleagues established a new society, 'Heart Failure Society of EuroAsia', in Türkiye. Our aim is to widen the knowledge of heart failure among the country, educating both the medical doctors and the general society. We also aim to contribute to research activities, especially investigate the incidence and prevalence of heart failure in the country, treatment tendencies and outcome. The first paper on the topic was just published in Lancet Regional Health Europe this year (stated below).

I have participated in the advisory board meetings on mechanical circulatory support organized by Medtronic and Abbot. I gave numerous presentations in Türkiye and in other countries on heart failure and especially on advanced heart failure.

It was great pleasure for me to be a member of the 'advanced heart failure committee' during the last eight years. I am looking forward to participate in and contribute for HFA.

1 Trends in heart failure between 2016 and 2022 in Türkiye (Trends-HF): a nationwide retrospective cohort study of 85 million individuals across entire population of all ages.

Celik A, Ural D, Sahin A, Colluoglu IT, Kanik EA, Ata N, Arugaslan E, Demir E, Ayvali MO, Ulgu MM, Temizhan A, Cavusoglu Y, Acar RD, **Nalbantgil S**, Asarcikli LD, Murat S, Birinci S, Yilmaz MB. *Lancet Reg Health Eur*. 2023 Sep 5;33:100723. doi: 10.1016/j.lanepe.2023.100723. eCollection 2023 Oct.

2 Effect of Aortic Valve Opening Pattern on Endothelial Function After Continuous-Flow Left Ventricular Assist Device Implantation.

Kaya E, Kocabaş U, Şimşek E, **Nalbantgil S**, Engin Ç, Özbaran M, Akilli A. *ASAIO J*. 2023 Oct 1;69(10):e429-e436. doi: 10.1097/MAT.0000000000002025.

3 Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the Heart Failure Association of the European Society of Cardiology.

Gustafsson F, Damman K, **Nalbantgil S**, Van Laake LW, Tops LF, Thum T, Adamopoulos S, Bonios M, Coats AJ, Crespo-Leiro MG, Mehra MR, Filippatos G, Hill L, Metra M, Jankowska E, de Jonge N, Kaye D, Masetti M, Parissis J, Milicic D, Seferovic P, Rosano G, Ben Gal T. *Eur J Heart Fail*. 2023 Apr;25(4):457-468. doi: 10.1002/ejhf.2814.

4 Characteristics and long-term survival of patients with left ventricular non-compaction cardiomyopathy.

Demir E, Bayraktaroğlu S, Çinkooğlu A, Candemir A, Candemir YB, Öztürk RO, Dadaş ÖF, Orman MN, Zoghi M, Akilli A, Ceylan N, Gürgün C, **Nalbantgil S**. *ESC Heart Fail*. 2022 Dec;9(6):4219-4229. doi: 10.1002/ehf2.14081. Epub 2022 Sep 16.

5 Prognostic Value of Cardiopulmonary Exercise Test Parameters in Ventricular Assist Device Therapy.

Dorken Gallastegi A, Ergi GD, Kahraman Ü, Yağmur B, Çinar E, Karapolat H, **Nalbantgil S**, Engin Ç, Yağdi T, Özbaran M. *ASAIO J*. 2022 Jun 1;68(6):808-813. doi: 10.1097/MAT.0000000000001571. Epub 2022 Sep 7.

6 .Heart failure with non-reduced ejection fraction: Epidemiology, pathophysiology, phenotypes, diagnosis and treatment approaches. Çavuşoğlu Y, Çelik A, Altay H, **Nalbantgil S**, Özden Ö, Temizhan A, Ural D, Ünlü S, Yilmaz MB, Zoghi M. *Turk Kardiyol Dern Ars*. 2022 May;50(Supp1):S1-S34. doi: 10.5543/tkda.2022.S1

7 Heart Failure Association of the European Society of Cardiology position paper on the management of left ventricular assist device-supported patients for the non-left ventricular assist device specialist healthcare provider: Part 2: at the emergency department.

Milicic D, Ben Avraham B, Chioncel O, Barac YD, Goncalvesova E, Grupper A, Altenberger J, Frigeiro M, Ristic A, De Jonge N, Tsui S, Lavee J, Rosano G, Crespo-Leiro MG, Coats AJS, Seferovic P, Ruschitzka F, Metra M, Anker S, Filippatos G, Adamopoulos S, Abuhazira M, Elliston J, Gotsman I, Hamdan R, Hammer Y, Hasin T, Hill L, Itzhaki Ben Zadok O, Mullens W, **Nalbantgil S**, Piepoli MF, Ponikowski P, Potena L, Ruhparwar A, Shaul A, Tops LF, Winnik S, Jaarsma T, Gustafsson F, Ben Gal T. *ESC Heart Fail*. 2021 Sep 14. doi: 10.1002/ehf2.13587.

8. Guidance on the management of left ventricular assist device (LVAD) supported patients for the non-LVAD specialist healthcare provider: executive summary.

Ben Gal T, Ben Avraham B, Milicic D, Crespo-Leiro MG, Coats AJS, Rosano G, Seferovic P, Ruschitzka F, Metra

M, Anker S, Filippatos G, Altenberger J, Adamopoulos S, Barac YD, Chioncel O, de Jonge N, Elliston J, Frigerio M, Goncalvesova E, Gotsman I, Grupper A, Hamdan R, Hammer Y, Hasin T, Hill L, Itzhaki Ben Zadok O, Abuhazira M, Lavee J, Mullens W, **Nalbantgil S**, Piepoli MF, Ponikowski P, Potena L, Ristic A, Ruhparwar A, Shaul A, Tops LF, Tsui S, Winnik S, Jaarsma T, Gustafsson F. Eur J Heart Fail. 2021 Oct;23(10):1597-1609. doi: 10.1002/ejhf.2327.

9. HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the non-hospital settings in the community.

Ben Avraham B, Crespo-Leiro MG, Filippatos G, Gotsman I, Seferovic P, Hasin T, Potena L, Milicic D, Coats AJS, Rosano G, Ruschitzka F, Metra M, Anker S, Altenberger J, Adamopoulos S, Barac YD, Chioncel O, De Jonge N, Elliston J, Frigeiro M, Goncalvesova E, Grupper A, Hamdan R, Hammer Y, Hill L, Itzhaki Ben Zadok O, Abuhazira M, Lavee J, Mullens W, **Nalbantgil S**, Piepoli MF, Ponikowski P, Ristic A, Ruhparwar A, Shaul A, Tops LF, Tsui S, Winnik S, Jaarsma T, Gustafsson F, Ben Gal T. ESC Heart Fail. 2021 Sep 14. doi: 10.1002/ehf2.13588

10 HFA of the ESC position paper on the management of LVAD-supported patients for the non-LVAD specialist healthcare provider Part 3: at the hospital and discharge.

Gustafsson F, Ben Avraham B, Chioncel O, Hasin T, Grupper A, Shaul A, **Nalbantgil S**, Hammer Y, Mullens W, Tops LF, Elliston J, Tsui S, Milicic D, Altenberger J, Abuhazira M, Winnik S, Lavee J, Piepoli MF, Hill L, Hamdan R, Ruhparwar A, Anker S, Crespo-Leiro MG, Coats AJS, Filippatos G, Metra M, Rosano G, Seferovic P, Ruschitzka F, Adamopoulos S, Barac Y, De Jonge N, Frigerio M, Goncalvesova E, Gotsman I, Itzhaki Ben Zadok O, Ponikowski P, Potena L, Ristic A, Jaarsma T, Ben Gal T. ESC Heart Fail. 2021 Sep 28. doi: 10.1002/ehf2.13590.

11 Creipo-Liero M, Metra M, Lars LH, Milicic D, Costanzo MR, Filippatos MR, Gustafsson F, Tsui S, Barge-Cabellero E, De Longe N, Frigero M, Hamdan R, Hasin T, Huslmann A, **Nalbantgil S**, Potena L, Bauersach J, Gkouziouta A, Ruhparwar A, Ristic AD, Straburzynka-Migaj E, McDonagh T, Sferovic P, Ruschitzka F. Advanced Heart Failure: a position statement of the Heart Failure Association of the European Society of Cardiology. 2018 doi:10.1002/ejhf.1236

12 **Nalbantgil S**, Cavusoglu Y, Bahri Akdeniz, Hakan Altay, Ahmet Çelik, Çağatay Engin, Tolga Sinan Güvenç, Bülent Mutlu, Gökçen Orhan, Bülent Ozin, Ahmet Temizhan, Dilek Ural, Nesligül Yıldırım, Mehmet Birhan Yılmaz

İleri Evre Kalp Yetersizliği Rehberi: A Guide on Advanced Heart Failure. Updates in Cardiology 2018:1 (Editor of the supplement)

Describe previous experience within the HFA, ESC and/or your National Cardiac/ HF Society
150 words maximum

I am a member of the Turkish Society of Cardiology. I have participated in preparation of annual meeting scientific program for the last 10 years. I also served as a scientific program committee member for International Society of heart and Lung Transplantation for the years 2016 / 2017 / 2022; topics covered were heart transplantation and mechanical circulatory support. I am a fellow of

ESC and a fellow of HFA. I participated in the 'advanced heart failure committee' for the last 8 years and contributed to three position papers prepared by HFA. I also participated in two HFA webinars: 15-Feb-2021: advanced heart failure: what is the right time to consider a LVAD and 24-January-2023: Advancing end-stage heart failure treatment: where are the women?. I contributed to several national and international HF trials as a principal investigator.

Why are you motivated to join the HFA Board or Nominating Committee?

150 words maximum

Participating in the 'advanced heart failure committee' has taught me a lot and improved my professional skills. Being part of the HFA keeps me motivated. The experience I gained helps me to widen my research and educational practice and apply to the work I do in my country. I would like to contribute to the global mission of HFA both in my country and the world.

How will you combine your HFA position with your daily clinical/research workload?

80 words maximum

I start working at 08:00 am and end my daily clinical practice generally by 17:00. I am planning to concentrate on HFA work early in the morning before starting my practice and at night time. The weekends will be dedicated to HFA.